Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.

  title={Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.},
  author={Lisa B Van Wagner and Sean W P Koppe and Elizabeth M. Brunt and Jeanne H Gottstein and Konstantina Gardikiotes and Richard M. Green and Mary Eugenia Rinella},
  journal={Annals of hepatology},
  volume={10 3},
INTRODUCTION The burden of non-alcoholic steatohepatitis (NASH) is growing and current pharmacologic treatments are limited by side effects and inconsistent efficacy. Pilot studies suggest that pentoxifylline (PTX) can reduce liver injury in patients with NASH. OBJECTIVE We sought to determine the tolerability of PTX and its effect on aminotransferases and liver histology in patients with NASH. MATERIAL AND METHODS Thirty patients with biopsy proven NASH were randomized in a 2:1 fashion to… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 46 extracted citations

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Indian journal of endocrinology and metabolism • 2018
View 2 Excerpts


Publications referenced by this paper.
Showing 1-10 of 28 references

Preventive effect of pentoxifylline on acute radiation damage via antioxidant and anti-inflammatory pathways

G Hepgul, S Tanrikulu, +4 authors E. Ademoglu
Dig Dis Sci • 2010

Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation • 2009

Pentoxifylline for Treatment of Nonalcoholic Fatty Liver Disease (NAFLD): A Randomized, Placebo-Controlled Study

W Buranawati, P Thoun-U-Thaisri, +3 authors U. Udomsubpayakul
Thai J Gastroenterol • 2007

Similar Papers

Loading similar papers…